IHS Chemical Week

EnviroTech :: R&D

Wacker’s Secretion Technology Studied

10:17 AM MDT | May 27, 2008 | Deepti Ramesh

Wacker Biotech (Jena, Germany), a wholly owned subsidiary of Wacker Chemie, says it has completed a feasibility study demonstrating that the company’s secretion technology can produce active protein comparable to that produced by mammalian cell cultures. “We believe the positive results of this study demonstrate that secreting E. coli systems can be a great tool for producing biologics in the future,” says Thomas Maier, managing director of Wacker Biotech. The study was aimed at determining the company’s efficacy of proprietary E. coli...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2014 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa